Why the study?
Does the combined application of olmesartan and lercanidipine improve blood pressure reduction and decrease microalbuminuria compared to monotherapy in patients with arterial hypertension 1-2 degrees and microalbuminuria?
Does the combined application of olmesartan and lercanidipine improve blood pressure reduction and decrease microalbuminuria compared to monotherapy in patients with arterial hypertension 1-2 degrees and microalbuminuria?
Combination therapy with olmesartan and lercanidipine provides superior blood pressure control and renoprotection (MAU reduction) compared to monotherapy in patients with grade 1-2 hypertension and microalbuminuria.
The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and corrective influence on diurnal BP profile were similar in groups of monotherapy with olmesartan and lercanidipine. In the group of combined application of the studied drugs target BP levels were achieved in 88% of cases in the monotherapy group and 78% (1G) and 76% (2 G).Revealed renoprotective effects of olmesartan and lercanidipine as when used in monotherapy and in combination in patients with arterial hypertension of 1-2 degrees, and MAU, revealed reliable decrease in MAU. The greatest reduction in MAU was achieved in the combination therapy group.
No takes yet. Share an insight, caveat, or question.
Евдокимова et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: